Latigo Biotherapeutics Inc.
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and…
1D
-5.1%
1W
-12.5%
1M
-39.3%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
PRICE TARGET LOW
US$36.00
CONSENSUS
US$52.25
MEDIAN
US$50.00
PRICE TARGET HIGH
US$73.00
No current analyst ratings available.
FREE FLOAT
23.3%
FLOAT SHARES
15,449,504
AVG. DAILY VOLUME (30D)
364,963
Sanofi
Sanofi
5AM Ventures VI, L.P.
5AM Ventures VI, L.P.
Westlake BioPartners Fund I, L.P.
Latigo Biotherapeutics Inc. is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in United States.
The CEO is Nima Farzan, the company employs around 66 people.
The IPO was on 07/08/2026; the stock trades on NASDAQ under the ticker LTGO.
The average price target is US$52.25, ranging from US$36.00 to US$73.00, with a median of US$50.00.
This is an external assessment, not a statement by Market Jury.
No, Latigo Biotherapeutics currently does not pay a dividend.
Comparable stocks include Corcept Therapeutics, Liquidia, Helus Pharma, Eli Lilly and Company, Johnson & Johnson, AbbVie, Merck & and UnitedHealth Group.
Clicking "Analyze stock" lets five strategies assess Latigo Biotherapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.